Advisory Services Network’s Century Therapeutics IPSC Stock Holding History

Advisory Services Network’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-407	Closed	-$920	–	3426
2026 Q1	$920	Buy	+407	New	+$856	﹤0.01%	4331
2025 Q4	–	Sell	-407	Closed	-$203	–	3060
2025 Q3	$203	Buy	+407	New	+$219	﹤0.01%	4216

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Advisory Services Network's IPSC Position: Q2 2026 in Review

Advisory Services Network sold out of Century Therapeutics (IPSC) in Q2 2026, closing a stake of 407 shares — an estimated $920 sold.

Advisory Services Network first reported a position in IPSC in Q3 2025 and held it in 2 quarters. The position peaked at $920 in Q1 2026. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Advisory Services Network reported no remaining Century Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 407 Century Therapeutics shares in Q2 2026, an estimated $920.
Advisory Services Network first reported a position in Century Therapeutics in Q3 2025 and held it in 2 quarters.
Advisory Services Network's Century Therapeutics position peaked at $920 in Q1 2026.
99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.